01 nov: Selskabsmeddelelse nr. 9/2018 - Årsregnskabsmeddelelse, FY 2017/1..
01 nov: Selskabsmeddelelse nr. 10/2018 - Årsrapport 2017/18 og Corporate ..
01-11-2018 08:34:01

Coloplast delivers solid full-year result and 8% growth for the sixth quarter running

Coloplast delivered 8% organic revenue growth in the fourth quarter of the 2017/18 financial year and 8% full-year organic revenue growth as well as a 31% EBIT margin. The company is guiding for ~8% organic revenue growth in 2018/19.

Coloplast delivered 8% organic revenue growth in the fourth quarter of its financial year, with reported revenue in DKK up by 6% to DKK 4,234m. Full-year organic revenue growth was also at 8%, while reported revenue in DKK was up by 6% to DKK 16,449m. While lifted by acquisitions, revenue growth measured in DKK was adversely affected by 4% due to currency developments, especially USD and ARS depreciating against DKK.

Relative to the 7% organic growth rates of the past three years, the full-year revenue growth marks a shift in momentum and an acceleration of growth in a market otherwise growing by 4-5%. Accelerating growth was indeed Coloplast’s goal when revising its long-term guidance in November 2017 with the ambition of increasing investments and accelerating growth during the period to 2019/2020 and growing at the upper end of the 7-9% range.

Full-year EBIT amounted to DKK 5,091m, a 1% increase in DKK, for an EBIT margin of 31%, compared to 32% in 2016/17. When measured at constant exchange rates and adjusted for the DKK 90m one-off revenue adjustment related to Veterans Affairs, EBIT was up by 4%, for an EBIT margin of 31% against 33% last year. The EBIT performance is in line with the company guidance and reflects an increase in innovation, sales, and marketing investments across all product categories.

  • “We’re delivering a strong fourth quarter performance at 8% revenue growth for the sixth quarter running, and we’re delivering highly satisfactory full-year results with growth across all regions. Even though 2017/18 was a year of investing for Coloplast, we’re still delivering solid results and we continue to grow at double the market rate. Obviously, I’m quite pleased with that,” said Coloplast CEO Lars Rasmussen.

The business areas produced the following full-year organic growth rates: Ostomy Care 9%, Continence Care 8%, Interventional Urology 10% and Wound & Skin Care 3%. A comprehensive pricing reform in Greece adversely affected the full-year growth performance in the Wound Care business.

Looking at sales by geographies, the European markets contributed 5% growth to FY sales, Other developed markets, driven mainly by the USA, delivered 11% revenue growth, while Emerging Markets provided a 14% increase.

  • “We’re seeing solid growth across our business areas, driven not least by our product launches and commercial investments. We will continue to invest up to 2% of revenue in innovation, sales, and marketing in 2018/19, so we can continue to develop and provide innovative products such as SenSura® Mio Concave. This new product portfolio has been very well received, and it is now available and eligible for reimbursement in ten countries. 2018/19 will be another year of investing, and in the first quarter we are launching SenSura® Mio Baby and SenSura® Mio Kids, designed specifically for premature babies and children up to 4 years,” said Mr Rasmussen.

Through the SenSura® Mio Baby and SenSura® Mio Kids portfolios, Coloplast sets a new standard for paediatric ostomy care products. The two new categories are scheduled for launch in all core markets within the next 12 months.

Financial guidance 2018/19

Coloplast is guiding for ~8% organic revenue growth at constant exchange rates. Reported growth in DKK forecast at 8-9%. EBIT margin of 30-31% expected at constant exchange rates with a reported EBIT margin of ~31% in DKK. The EBIT margin forecast reflects additional investments of up to 2% of revenue for innovation and sales and marketing purposes.

CONTACTS

Lina Danstrup

Senior Media Relations Manager, Corporate Communications

+45 49 11 26 07

dklina@coloplast.com

Ellen Bjurgert

Vice President, Investor Relations

+45 49 11 33 76

dkebj@coloplast.com

Financial highlights and key ratios

 DKKm

2017/18

2016/17

 

Change

 

2017/18

Q4

2016/17

Q4

Change

Revenue 16,449 15,528 6%   4,234 3,980 6%
EBIT 5,091 5,024 1%   1,415 1,319 7%
EBIT margin (at constant exchange rates) 31% 33%

(adjusted for VA)

    33% 34%  
EBIT margin (in DKK) 31% 32%     33% 33%  
Profit for the period 3,845 3,797 1%   1,039 1,010 3%

Sales performance by business area

 DKKm

2017/2018

 

2016/2017

Organic growth

Reported growth

Ostomy Care 6,643 6,291 9% 6%
Continence Care 5,943 5,543 8% 7%
Interventional Urology 1,740 1,641 10% 6%
Wound & Skin Care 2,140 2,143 3% 0%
Other matters   (90)   1%

Revenue

16,449

15,528

8%

6%

 (DKKm)

2017/2018

Q4

2016/2017

Q4

Organic growth

Reported growth

Ostomy Care 1,700 1,597 9% 6%
Continence Care 1,520 1,424 7% 7%
Interventional Urology 432 390 10% 11%
Wound & Skin Care 582 569 4% 2%

Revenue

4,234

3,980

8%

6%

Financial guidance for 2017/18

 

Guidance for 2018/19

Guidance for 2018/19 (DKK)

Sales growth

~8% (organic) 8-9%

EBIT margin

30-31% (at constant exchange rates) ~31%

Capital expenditure

- ~750m

Tax rate

- ~23%

Attachment

logo.png

Relateret indhold
12 jun - 
Coloplast/Berenberg: Kursridt er besynderligt - mulig m..
12 jun - 
Aktier/åbning: Novo og Ambu dykker efter stigninger - P..
12 jun - 
Aktier/tendens: Nyt om studiedata kan sikre Novo Nordis..
Relateret debat
17 jun - 
Ja den har toppet mener jeg
17 jun - 
Nix! Coloplast kender kun en vej! Det er op.
17 jun - 
Hvad tænker i om coloplast? er den hyppet nok nu og kom..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Finanskommentaren: Comeback til aktiemarkederne er rykket tættere på

19-06-2019 12:30:00
Af Henrik Henriksen, chefstrateg, VellivSiden Trumps skattelettelser gav aktiemarkederne et markant løft i 2017, har markederne befundet sig i et limbo med skiftende retninger op og ned. Når vi ser frem mod 2. halvår 2019, er der mange mulige forløb, men især to ting vil være med til at udstikke retningen for den næste større bevægelse. For det første handelskonflikten mellem USA og Kina - for sel..

Sydbank ser større afkastpotentiale i USA end i Europa

Relaterede nyheder
19-06-2019 10:35:03
Sydbank fastholder i en ny udgave af sin aktiestrategi et såkaldt gult afkastbarometer på de globale aktiemarkedet, hvilket dækker over en forventning om beherskede, men trods alt positive aktieafkast i det kommende år.Aktierne ventes her at være hjulpet af lavrente- og muligvis også likviditetslykkepiller fra centralbankerne, lyder det fra aktieanalysechef Jacob Pedersen fra Sydbank, som ser stør..

Aktier/tendens: Ambu tæt på halvering efter direktør-exit i maj

19-06-2019 08:26:48
Ambu fik klaps tirsdag efter nedjusteringer i indeværende regnskabsår og næste. Og med et kursfald på over 14 pct. på en enkelt dag kommer medicoselskabet til at tage en del fokus onsdag i et marked, der generelt ventes at åbne udramatisk.Dramatikken står for Ambus regning, og aktien har været ude i et sandt stormvejr i år - orkanstyrken tog til, da selskabets tidligere direktør, Lars Marcher, ove..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Finanskommentaren: Comeback til aktiemarkederne er rykket tættere på
2
Aktier/tendens: Ambu tæt på halvering efter direktør-exit i maj
3
Vestas/Woodmac: Vil også være størst i 2019 - USA det største marked
4
Britisk hedgefond lukker Ambu-short
5
Missil rammer udenlandske olieselskaber i irakiske Basra

Relaterede aktiekurser

Coloplast B A/S 762,20 0,1% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
19. juni 2019 21:17:33
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190527.1 - EUROWEB3 - 2019-06-19 21:17:33 - 2019-06-19 21:17:33 - 1 - Website: OKAY